$EVOK
Evoke Pharma Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023040998 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.563M $1.131M
YoY Change 87.82% 144.99%
Cost Of Revenue $30.00K $57.36K
YoY Change -66.58% -15.36%
Gross Profit $1.530M $1.074M
YoY Change 106.11% 172.57%
Gross Profit Margin 97.9% 94.93%
Selling, General & Admin $3.131M $2.766M
YoY Change 19.77% 19.48%
% of Gross Profit 204.67% 257.55%
Research & Development $0.00 $92.36K
YoY Change -100.0% -51.77%
% of Gross Profit 0.0% 8.6%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.166M $2.916M
YoY Change 15.36% 13.26%
Operating Profit -$1.603M -$1.784M
YoY Change -16.16% -15.54%
Interest Expense $126.0K $124.7K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$90.47K -$83.49K
YoY Change -10.7% -30.85%
Pretax Income -$1.690M -$1.868M
YoY Change -16.08% -16.36%
Income Tax
% Of Pretax Income
Net Earnings -$1.694M -$1.868M
YoY Change -15.89% -16.36%
Net Earnings / Revenue -108.39% -165.1%
Basic Earnings Per Share -$0.51 -$0.56
Diluted Earnings Per Share -$0.51 -$0.56
COMMON SHARES
Basic Shares Outstanding 3.343M 3.343M
Diluted Shares Outstanding 3.343M 3.343M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.960M $7.006M
YoY Change -51.74% -47.91%
Cash & Equivalents $6.000M $7.000M
Short-Term Investments
Other Short-Term Assets $98.09K $11.55K
YoY Change 749.23% 0.0%
Inventory $504.9K $513.7K
Prepaid Expenses $37.86K $371.3K
Receivables $1.230M $1.024M
Other Receivables $0.00 $0.00
Total Short-Term Assets $7.840M $8.927M
YoY Change -40.86% -38.03%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $52.84K
YoY Change -93.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $13.37K $52.84K
YoY Change -91.3%
TOTAL ASSETS
Total Short-Term Assets $7.840M $8.927M
Total Long-Term Assets $13.37K $52.84K
Total Assets $7.853M $8.980M
YoY Change -41.44% -37.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.415M
YoY Change 37.16% 71.66%
Accrued Expenses $840.0K $665.8K
YoY Change -2.02% 25.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.240M $2.081M
YoY Change 19.3% 53.8%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $1.490M $1.360M
YoY Change 49.05% 58.12%
Total Long-Term Liabilities $6.486M $6.360M
YoY Change 8.11% 8.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.240M $2.081M
Total Long-Term Liabilities $6.486M $6.360M
Total Liabilities $8.727M $8.441M
YoY Change 10.78% 17.02%
SHAREHOLDERS EQUITY
Retained Earnings -$121.5M -$119.8M
YoY Change 6.68% 7.09%
Common Stock $120.6M $120.3M
YoY Change 1.01% 1.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$873.8K $538.4K
YoY Change
Total Liabilities & Shareholders Equity $7.853M $8.980M
YoY Change -41.44% -37.66%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.694M -$1.868M
YoY Change -15.89% -16.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.040M -$1.206M
YoY Change -5.53% -12.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.040M -1.206M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -1.040M -1.206M
YoY Change -5.53% -120.98%
FREE CASH FLOW
Cash From Operating Activities -$1.040M -$1.206M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001403708
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36075
dei Entity Registrant Name
EntityRegistrantName
EVOKE PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
345-1494
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EVOK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3343070
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7006431
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9843699
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1023813
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
624832
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
371348
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
952954
CY2023Q2 us-gaap Inventory Net
InventoryNet
513712
CY2022Q4 us-gaap Inventory Net
InventoryNet
289378
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2023Q2 us-gaap Assets Current
AssetsCurrent
8926855
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11722414
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52842
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
129074
CY2023Q2 us-gaap Assets
Assets
8979697
CY2022Q4 us-gaap Assets
Assets
11851488
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1415309
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
934312
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
612932
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
591158
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52842
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
129074
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2081083
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1654544
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1360240
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1112295
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6360240
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6112295
CY2023Q2 us-gaap Liabilities
Liabilities
8441323
CY2022Q4 us-gaap Liabilities
Liabilities
7766839
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
334
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
334
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120296170
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
119731458
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119758130
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115647143
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
538374
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8979697
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11851488
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1131368
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
461795
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1941777
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
880175
CY2023Q2 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
57357
CY2022Q2 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
67774
evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
107948
evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
90535
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
92357
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
191478
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
159347
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
233194
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2766077
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2315175
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5614018
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4720251
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
2915791
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2574427
us-gaap Operating Expenses
OperatingExpenses
5881313
us-gaap Operating Expenses
OperatingExpenses
5043980
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1784423
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2112632
us-gaap Operating Income Loss
OperatingIncomeLoss
-3939536
us-gaap Operating Income Loss
OperatingIncomeLoss
-4163805
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
41164
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3910
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
76494
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4705
CY2023Q2 us-gaap Interest Expense
InterestExpense
124658
CY2022Q2 us-gaap Interest Expense
InterestExpense
124658
us-gaap Interest Expense
InterestExpense
247945
us-gaap Interest Expense
InterestExpense
247945
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83494
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120748
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-171451
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-243240
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1867917
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2233380
us-gaap Net Income Loss
NetIncomeLoss
-4110987
us-gaap Net Income Loss
NetIncomeLoss
-4407045
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3156925
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3156925
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2944183
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2944183
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
284572
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2126151
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
280140
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1867917
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
538374
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381061
CY2022Q1 evok Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
3548
CY2022Q1 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
171521
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1934011
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
366924
CY2022Q2 evok Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
145445
CY2022Q2 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
7123455
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2233380
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7191010
us-gaap Net Income Loss
NetIncomeLoss
-4110987
us-gaap Net Income Loss
NetIncomeLoss
-4407045
evok Non Cash Lease Expense
NonCashLeaseExpense
76232
us-gaap Share Based Compensation
ShareBasedCompensation
564712
us-gaap Share Based Compensation
ShareBasedCompensation
747985
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
398981
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
70450
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-357272
evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-545455
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
480997
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-61975
evok Accrued Compensation
AccruedCompensation
-21774
evok Accrued Compensation
AccruedCompensation
-9348
evok Accrued Interest Expense
AccruedInterestExpense
247945
evok Accrued Interest Expense
AccruedInterestExpense
247945
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-76232
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2837268
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2988737
evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
7443969
evok Payment Of Common Stock Offering Cost At Market Offering
PaymentOfCommonStockOfferingCostAtMarketOffering
148993
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7294976
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2837268
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4306239
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9843699
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9144710
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7006431
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13450949
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7000000.0
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12 reverse stock split
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2100000
CY2023Q2 evok Minimum Market Value Of Listed Securities
MinimumMarketValueOfListedSecurities
2500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q2 evok Bad Debt Expense
BadDebtExpense
0
CY2022Q2 evok Bad Debt Expense
BadDebtExpense
0
evok Bad Debt Expense
BadDebtExpense
0
evok Bad Debt Expense
BadDebtExpense
0
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
355000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
239000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
159000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
50000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
645601
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
491851
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
645601
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
491851
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-10-31
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
53000
CY2023Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y3M29D
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
40112
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
37281
us-gaap Operating Lease Payments
OperatingLeasePayments
80223
us-gaap Operating Lease Payments
OperatingLeasePayments
74562
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000.0
evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
139972
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
280140
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
366924
us-gaap Share Based Compensation
ShareBasedCompensation
564712
us-gaap Share Based Compensation
ShareBasedCompensation
747985
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D

Files In Submission

Name View Source Status
0000950170-23-040998-index-headers.html Edgar Link pending
0000950170-23-040998-index.html Edgar Link pending
0000950170-23-040998.txt Edgar Link pending
0000950170-23-040998-xbrl.zip Edgar Link pending
evok-20230630.htm Edgar Link pending
evok-20230630.xsd Edgar Link pending
evok-ex10_1.htm Edgar Link pending
evok-ex31_1.htm Edgar Link pending
evok-ex31_2.htm Edgar Link pending
evok-ex32_1.htm Edgar Link pending
evok-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img215259106_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
evok-20230630_def.xml Edgar Link unprocessable
evok-20230630_lab.xml Edgar Link unprocessable
evok-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
evok-20230630_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
evok-20230630_cal.xml Edgar Link unprocessable